SCHEMBL7659118

SCHEMBL7659118

Nc1nc2cc(-c3nc4cc(-c5nc6cc(-c7ccccc7)ccc6[nH]5)ccc4[nH]3)ccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.54
▸ SMN1; SMN2 Q16637 9/20 0.54
▸ NPC1 O15118 8/20 0.54
▸ RAB9A P51151 8/20 0.54
▸ KDM4E B2RXH2 8/20 0.54
▸ HPGD P15428 8/20 0.54
▸ HSD17B10 Q99714 5/20 0.54
▸ TP53 P04637 3/20 0.54
▸ PRMT1 Q99873 1/20 0.52
▸ GAA P10253 3/20 0.51
▸ MAPT P10636 7/20 0.51
▸ GFER P55789 2/20 0.51
▸ GLA P06280 2/20 0.51
▸ HTT P42858 1/20 0.51
▸ RCE1 Q9Y256 1/20 0.51
▸ MEN1 O00255 5/20 0.50
▸ KMT2A Q03164 5/20 0.50
▸ POLB P06746 4/20 0.50
▸ PKM P14618 3/20 0.50
▸ NFKB1 P19838 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3827667 0.92 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL22649095 0.87 NPC1 (0.67) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL7653231 0.87 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL7652952 0.87 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL417825 0.84 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL27825168 0.83 PRMT1 (0.54) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL57009 0.82 POLB (0.57) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL7654167 0.82 NPC1 (0.51) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL28793724 0.82 PRMT1 (0.52) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL7656217 0.82 NPC1 (0.51) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6399642-B2 TRIS BENZIMIDAZOLES; FUNGICIDES, ANTICARCINOGENIC AGENTS, ENZYME INHIBITOR RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2002-06-04 — — US disclosed
US-20010009919-A1 Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2001-07-26 — — US disclosed
US-6221892-B1 Heterocyclic topoisomerase poisons THE STATE OF UNIVERSITY OF NEW JERSEY, RUTGERS 2001-04-24 — — US disclosed
EP-1054870-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-11-29 — — EP disclosed
US-6063801-A Heterocyclic topoisomerase poisons RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2000-05-16 — — US disclosed
WO-1999041241-A1 HETEROCYCLIC TOPOISOMERASE POISONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010009919-A1 Heterocyclic topoisomerase poisons TOP1, TOP2A, TOP2B ALDH1A1 2485/4885SMN1; SMN2 1095/4885NPC1 2875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback